The Dan L Duncan Cancer Center strongly supports the development of investigator-initiated early phase clinical trials. Fifteen investigator-initiated clinical trials that did not initially have external support have been implemented during the last 3 years and an additional 10 are in the final stages of development. The Protocol-Specific Research Support (PSRS) program provides funding for regulatory and research coordinator support for the coordination and implementation of such novel clinical trials initiated by DLDCC investigators. PSRS resources are specifically targeted to high-priority investigator-initiated phase 1 and feasibility trials judged to be of high merit at the time of scientific review by the PRMS executive committee Criteria for support include innovation and the presence of correlative science studies performed in collaboration with DLDCC basic or translational scientists or that utilized DLDCC shared resources. The senior clinical cancer center leadership has identified support of young investigators as a priority and is also focusing on increasing the diversity of cancer center clinical investigators. Consequently, 3 of the 4 studies supported at present are led by young investigators, 4 of the investigators are minorities and all studies have associated correlative studies. Metrics for evaluation of the protocol specific support program include subsequent receipt of peer-reviewed funding and completion and publication of the study. The PSRS program is evaluated by both the Executive Committee and the External Advisory Board. A goal in the next 3 years is to support investigator-initiated studies that emanate from the developing programs or areas that are of high priority to develop within the DLDCC.
The Dan Duncan Cancer Center is committed to supporting early phase novel clinical trials developed by investigators in this center. This resource provides research support for investigators to develop and initiate such studies.
|Giudice, Jimena; Loehr, James A; Rodney, George G et al. (2016) Alternative Splicing of Four Trafficking Genes Regulates Myofiber Structure and Skeletal Muscle Physiology. Cell Rep 17:1923-1933|
|Kundu, S T; Byers, L A; Peng, D H et al. (2016) The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene 35:173-86|
|TreviÃ±o, Lindsey S; Bolt, Michael J; Grimm, Sandra L et al. (2016) Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. Mol Endocrinol 30:158-72|
|Gargett, Tessa; Yu, Wenbo; Dotti, Gianpietro et al. (2016) GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther 24:1135-49|
|Aisiku, Imo P; Yamal, Jose-Miguel; Doshi, Pratik et al. (2016) Plasma cytokines IL-6, IL-8, and IL-10 are associated with the development of acute respiratory distress syndrome in patients with severe traumatic brain injury. Crit Care 20:288|
|Li, Yiting; Nakka, Manjula; Kelly, Aaron J et al. (2016) p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma. Cancer Res 76:4002-11|
|Ren, Yi A; Liu, Zhilin; Mullany, Lisa K et al. (2016) Growth Arrest Specific-1 (GAS1) Is a C/EBP Target Gene That Functions in Ovulation and Corpus Luteum Formation in Mice. Biol Reprod 94:44|
|Oliver, Nora T; Hartman, Christine M; Kramer, Jennifer R et al. (2016) Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals. AIDS :|
|Ramos, Carlos A; Savoldo, Barbara; Torrano, Vicky et al. (2016) Clinical responses with T lymphocytes targeting malignancy-associated Îº light chains. J Clin Invest 126:2588-96|
|PethÅ‘, ZoltÃ¡n; Tanner, Mark R; Tajhya, Rajeev B et al. (2016) Different expression of Î² subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes. Arthritis Res Ther 18:103|
Showing the most recent 10 out of 683 publications